Deutetrabenazine (US brand name Austedo®) is a vesicular monoamine transporter 2 (VMAT2) inhibitor. Here is basic information about this medication.
Treatment of chorea associated with Huntington’s disease
Treatment of tardive dyskinesia in adults
A. When patients are not being switched from tetrabenazine (Xenazine®)
1. Chorea associated with Huntington’s disease
Initial: 6 mg/day orally
Recommended: 6 mg – 48 mg/day
Maximum: 48 mg/day
2. Tardive dyskinesia
Initial: 12 mg/day
Recommended: 12 mg– 48 mg/day
Maximum: 48 mg/day
B. When patients are being switched from tetrabenazine (Xenazine®) to deutetrabenazine (Austedo®)[table id=3 /]
Titrate at weekly intervals by 6 mg per day based on reduction of chorea or tardive dyskinesia, and tolerability, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily).
Administer total daily dosages of 12 mg or above in two divided doses.
Administer deutetrabenazine with food.
Patients should swallow whole tablets without chewing, crushing, or breaking tablets.
For patients at risk for QT prolongation, assess the QT interval before and after increasing total deutetrabenazine dosage above 24 mg per day
Dosage forms and strengths
Tablets: 6 mg, 9 mg, and 12 mg
Please refer to Prescribing Information (see link below) for complete discussion of dosage, administration, warnings and precautions, contraindications, etc.
Copyright © 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other lay persons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.